Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30637543 | 0.91 | OPRM1 (0.62) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL29794254 | 0.91 | OPRM1 (0.62) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL34461924 | 0.88 | OPRD1 (0.67) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL30463400 | 0.87 | OPRM1 (0.62) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL29576785 | 0.85 | SLC6A2 (0.74) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL30423227 | 0.85 | OPRM1 (0.74) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL29571797 | 0.85 | OPRM1 (0.74) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL30957418 | 0.85 | SLC6A2 (0.62) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL30503063 | 0.84 | SLC6A2 (0.53) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL30957420 | 0.83 | OPRM1 (0.61) | OPRM1OPRD1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331779-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | SHAANXI MICOT TECHNOLOGY CO., LTD. (CN) | 2023-10-19 | — | — | US | claimed |
| EP-4212542-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | Shaanxi Micot Technology Limited Company (CN) | 2023-07-19 | — | — | EP | claimed |
| WO-2022052471-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | 陕西麦科奥特科技有限公司 | 2022-03-17 | — | — | WO | claimed |
| US-20230331779-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | SHAANXI MICOT TECHNOLOGY CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| EP-4212542-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | Shaanxi Micot Technology Limited Company (CN) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022052471-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | 陕西麦科奥特科技有限公司 | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331779-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | CALCR, BID, CASR | OPRM1 379/4885OPRD1 315/4885SLC6A2 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.